Author

T. Hiramoto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Ojida· 1 shared A. Sato· 1 shared D. Takahashi· 1 shared E. Kawanishi· 1 shared E. Morishita· 1 shared H. Isogai· 1 shared H. Sawa· 1 shared J. M. M. Caaveiro· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. Ojida

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cure of congenital purpura fulminans via expression of engineered protein C through neonatal genome editing in mice

T. Togashi, N. Baatartsogt, Y. Nagao, Y. Kashiwakura, M. Hayakawa, N. Kamoshita, T. Hiramoto, T. Fujiwara, E. Morishita, O. Nureki, T. Ohmori

The paper demonstrates that ectopic expression of an engineered protein C via neonatal genome editing cures congenital protein C deficiency in mice.

bioRxiv · Feb 26, 2023Bioengineering

Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for SARS-CoV-2 3CL Protease

Y. Hirose, N. Shindo, M. Mori, S. Onitsuka, H. Isogai, R. Hamada, T. Hiramoto, J. Ochi, D. Takahashi, T. Ueda, J. M. M. Caaveiro, Y. Yoshida, S. Ohdo, N. Matsunaga, S. Toba, , A. Ojida

The paper identifies a new class of covalent inhibitors for SARS-CoV-2 3CL protease with chlorofluoroacetamide warhead, showing potent antiviral activity comparable to nirmatrelvir.

bioRxiv · Jun 5, 2022Biochemistry